Seroatlas · Human Serome Atlas

IMPA2

Inositol monophosphatase 2

Also known as: IMPA2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O14732
Gene: IMPA2
Ensembl: ENSG00000141401
Chromosome: 18
Canonical length: 288 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Mitochondria
Quaternary structure: Homodimer

OverviewNCBI Gene

This locus encodes an inositol monophosphatase. The encoded protein catalyzes the dephosphoylration of inositol monophosphate and plays an important role in phosphatidylinositol signaling. This locus may be associated with susceptibility to bipolar disorder. [provided by RefSeq, Jan 2011]

Canonical amino-acid sequenceUniProt

288 residues, UniProt reviewed canonical sequence.

>O14732|IMPA2
     1  MKPSGEDQAA LAAGPWEECF QAAVQLALRA GQIIRKALTE EKRVSTKTSA ADLVTETDHL
    61  VEDLIISELR ERFPSHRFIA EEAAASGAKC VLTHSPTWII DPIDGTCNFV HRFPTVAVSI
   121  GFAVRQELEF GVIYHCTEER LYTGRRGRGA FCNGQRLRVS GETDLSKALV LTEIGPKRDP
   181  ATLKLFLSNM ERLLHAKAHG VRVIGSSTLA LCHLASGAAD AYYQFGLHCW DLAAATVIIR
   241  EAGGIVIDTS GGPLDLMACR VVAASTREMA MLIAQALQTI NYGRDDEK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IMPA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.24
Highest tissue expression: 339 nTPM

Expression across tissuesHPA

Tissue

pancreas: 339 nTPM
skeletal muscle: 260 nTPM
skin: 153 nTPM
esophagus: 134 nTPM
kidney: 133 nTPM
tongue: 84 nTPM

Single-cell type

pancreatic acinar cells: 885 nCPM
esophageal basal cells: 478 nCPM
esophageal suprabasal cells: 408 nCPM
esophageal apical cells: 380 nCPM
extravillous trophoblasts: 378 nCPM
suprabasal keratinocytes: 244 nCPM

Immune cell

neutrophil: 32 nTPM
eosinophil: 26 nTPM
classical monocyte: 11 nTPM
basophil: 9.4 nTPM
myeloid DC: 9 nTPM
intermediate monocyte: 8.7 nTPM

Brain region

choroid plexus: 8.5 nTPM
basal ganglia: 4 nTPM
cerebral cortex: 3.2 nTPM
thalamus: 2.8 nTPM
hippocampal formation: 2.6 nTPM
amygdala: 2.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.92
gnomAD pLI: 0
gnomAD missense Z: 0.85
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of IMPA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

IMPA1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IMPA2 as an antibody target. Whether an autoantibody or antibody against IMPA2 could matter depends on whether native IMPA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IMPA2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label IMPA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...